← All trials
NCT03123406
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2017
- Primary completion
- Apr 21, 2019
- Completion date
- Sep 27, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 750
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Kyowa Hakko KirinLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Foshan First People's HospitalOverall official - principal investigator
- Sichuan Huaxi HopsitalOverall official - principal investigator
- Xiamen UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- Tsinghua UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Nanjing UniversityStudy chair
- Anhui Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.